Cardiac Diseases

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

C
CENTOGENEGermany - Rostock
1 program
Biomarker for Pompe Disease (BioPompe)N/A1 trial
Active Trials
NCT01457443Withdrawn0Est. Dec 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CENTOGENEBiomarker for Pompe Disease (BioPompe)

Clinical Trials (1)

NCT01457443CENTOGENEBiomarker for Pompe Disease (BioPompe)

Biomarker for Pompe Disease (BioPompe)

Start: Aug 2018Est. completion: Dec 20210
N/AWithdrawn

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space